trending Market Intelligence /marketintelligence/en/news-insights/trending/pNItBpaQ_eGJfSFyqwnpQQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Applied Therapeutics' metabolic disorder drug helps reduce symptoms; stocks soar

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Applied Therapeutics' metabolic disorder drug helps reduce symptoms; stocks soar

Applied Therapeutics Inc. said its medicine AT-007 was better than placebo in treating a rare metabolic disorder called galactosemia.

According to the results of a mid-stage study called Action-Galactosemia, the highest tested dose of AT-007 helped reduce plasma galactitol by between 45% to 54% in patients from the time treatment began. Those on placebo saw no substantial change in the toxic metabolite which is the cause of long-term complications related to growth, intellectual disability, liver disease and the kidneys.

Galactosemia, for which there are no known cures or therapies, affects the body's ability to process a sugar called galactose. High levels of galactose, which is derived from lactose in food, are then converted by the body into a toxic sugar alcohol called galactitol.

AT-007 was well tolerated and no drug-related adverse events were seen. The company said in a Jan. 8 press release that it will present detailed results of the study at a medical conference in April.

The New York-based biopharmaceutical company, which went public in 2019, saw its stock rise by 24.62% to $32.60 in pre-market trading on Jan. 8 on Nasdaq.

Applied Therapeutics plans to file for U.S. regulatory approval of the drug this year, with further plans to evaluate long term safety of AT-007 in adult patients and study its effects in children.

AT-007 holds the FDA's orphan-drug designation for treating galactosemia.